Fig. 3
From: The genomic alterations in glioblastoma influence the levels of CSF metabolites
CSF from GBM patients exhibits significantly higher levels of (A) carnitine, (B) 2-methylbutyrylcarnitine, (C) shikimate, (D) aminobutanal, € uridine, (F) N-acetylputrescine, and (G) farnesyl diphosphate than control CSF. Each colored dot represents a patient, small black dot indicates samples that are 1.5 times the interquartile range above the upper quartile or below the lower quartile